Eliquis: GI Bleeds, Strokes, or Severe Uncontrolled Bleeding
We are not accepting new cases at this time.
Eliquis (apixaban) was approved by the FDA in 2012. Pfizer and Bristol-Myers Squibb are the two drug companies responsible for Eliquis.
Eliquis does not have an FDA-approved specific antidote for a patient experiencing a trauma-induced bleeding event or needing emergency surgery.
Our law firm is handling Eliquis cases which involve people who had excessive bleeding, bled to death, or experienced other serious side effects of Eliquis.
These medical conditions may have been caused by the use of Eliquis:
• Serious Bleeding Events
• Irreversible Fatal Bleeding Events
• Trauma-induced Atypical Bleeding Incidents
• Gastrointestinal (GI) Bleeds
• Rectal Bleeding
• Brain Hemorrhage
• Intracranial Hemorrhage
• Hemorrhagic Stroke
• Cardiac Bleeds
• Heart Attacks
• Myocardial Infarction (MI)
• Acute Coronary Syndrome (ACS)
While an Eliquis antidote, or reversal agent, will someday be available to help patients suffering an acute bleed, unfortunately it is too late for some people who suffered serious bleeding events or bled to death, already.
Recent Side Effects Case Evaluations
Eliquis – Cerebral Hemorrhage (CVA); Death – 69 yr old woman
Eliquis – Gastrointestinal (GI) Bleeding; Death – 88 yr old man
Eliquis – Fatal Internal Bleeding – 76 yr old woman
Eliquis – Brain Bleed – 74 yr old woman
Eliquis – Fatal Internal Bleeding – 67 yr old man
Eliquis – Gastrointestinal (GI) Bleeding – 59 yr old man
Eliquis – Massive Cerebral Hemorrhage; Death – 81 yr old man
Eliquis – Gastrointestinal (GI) Bleeding; Death – 72 yr old man
Eliquis – Serious Bleeding Event – 82 yr old woman
Eliquis – Hemorrhagic Stroke – 92 yr old woman
Most Recent Article About This Drug
In the federal court system, there are now more than 50 Eliquis lawsuits filed, and more of these drug injury and death cases are expected. Given this situation, in early February 2017 the United States Judicial Panel on Multidistrict Litigation (JPML) established this consolidation of all federal court Eliquis cases, IN RE: ELIQUIS (APIXABAN) PRODUCTS LIABILITY LITIGATION — MDL No. 2754.
To read more of this article, click below:
[W]e find that these actions involve common questions of fact, and that centralization will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. All the actions share common factual questions arising out of allegations that plaintiffs suffered severe bleeding and related injuries as a result of taking Eliquis (apixaban), that defendants did not conduct sufficient testing of the drug, and that defendants’ warnings and instructions as to the alleged risks, including the unavailability of a reversal agent to counteract bleeding, were inadequate. Issues concerning the design, testing, manufacture, regulatory approval, labeling, and marketing of Eliquis thus are common to all actions….
We conclude that the Southern District of New York is an appropriate transferee district for this litigation. Common defendants BMS and Pfizer both have their corporate headquarters within the district, and therefore relevant documents and witnesses are likely to be located there. Sixteen actions on the motion and three potential tag-along actions are pending there.
In addition to the federal court Eliquis cases, there are a significant number of Eliquis lawsuits filed in the California state court system. As a result, a petition to coordinate those California Eliquis cases was submitted to the Chair of the Judicial Council seeking to establish a consolidation, there, which would be similar to the federal court Eliquis MDL.
In California, if that petition to coordinate the Eliquis lawsuits — which was submitted to the Chair of the Judicial Council (the Chief Justice) and then assigned to a motion judge for determination — is granted, its result would be called the California Eliquis JCCP (Judicial Council Coordination Proceedings).
It is currently expected that the determination about the creation of this California Eliquis JCCP will be made in the next couple of months.[Read this article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Defendants BMS And Pfizer Ask For Eliquis Federal Court Consolidation
- Is Eliquis A Safe Alternative To Warfarin For Patients On Dialysis?
- No Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet
- Eliquis Lawsuits Being Filed Across The Country In Increasing Numbers
- Antidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval
- Possible Blood Level Testing For Eliquis / Xarelto / Pradaxa / Savaysa
- Eliquis, Savaysa, And Xarelto Worry Doctors Because No Antidote, Still
- Eliquis Might Be Safer Than Xarelto, But Neither Has Approved Antidote
- Xarelto / Savaysa / Pradaxa / Eliquis: Effect Of Platelet Inhibitors
- No Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding
- Eliquis Antidote Will Come Too Late For People Who Suffered Serious Bleeding Events, Some Which Caused The Deaths Of Patients
- Because No Antidote For Eliquis Is Available To Reverse The Effects Of Anticoagulation, There Have Been Irreversible Life-Threatening And Fatal Bleeding Events